Hemophilia A occurs due to a factor VIII deficiency. It is an X-linked chromosomal disease also known as classic hemophilia. Patients inherit the condition as an X-linked trait, and as a result, males are primarily affected by the condition, while females are the carriers of the trait. The condition generally involves genetic inheritance, wherein the trait is passed onto the children by parents. About 33% of the cases involve spontaneous mutation. Individuals who are affected suffer hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds.

Low diagnosis rate is a key contributor driving the hemophilia A treatment market globally. According to a World Federation of Hemophilia 2017 report, globally, there are around 400,000 patients with hemophilia. Out of the total population of hemophilia patients, hemophilia A patients account for around 80%. Hemophilia A is about four times as common as hemophilia B and occurs in 1 in 5,000 live male births. Globally, only about 30% of patients with hemophilia are diagnosed, partly due to lower awareness levels about the condition among the general population. Hemophilia patients exhibit three forms of the condition: mild, moderate, or severe, depending on the level of clotting factor in the blood. A severe form of the condition affects 40% of hemophilia patients, who are vulnerable to several bleeds per month without treatment. Mild and moderate hemophilia can go undiagnosed for years due to variable bleed rates, thus affecting the overall diagnosis rate. Geographically, developed countries have a relatively higher diagnosis rate as compared to developing countries, owing to increased government initiatives for improving hemophilia awareness levels among the general population. With an increase in initiatives aimed at improving awareness levels about hemophilia, the diagnosis rate is expected to rise, in turn, boosting demand for therapies used for managing this condition.

Hemophilia drug manufacturers and government and non-government organizations are focusing on nationwide campaigns to create awareness about the condition among the general population. Each year, April 17th is observed as World Hemophilia Day. On this day, organizations such as the World Federation of Hemophilia (WFH) and local governments and other groups in different countries come together to raise public awareness among the hemophilia community. National news media campaigns and social media campaigns have been used to educate people with hemophilia to help them effectively monitor and manage this condition.

The global hemophilia A treatment market can be segmented based on product, distribution channel, and geography. In terms of product, the global hemophilia A treatment market can be divided into recombinant coagulation factor concentrates, plasma-derived coagulation factor concentrates, and others. Based on distribution channel, the global hemophilia A treatment market can be divided into retail pharmacies, hospital pharmacies, and others.

In terms of geography, the global hemophilia A treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global hemophilia A treatment market due to the presence of a large patient pool suffering from hemophilia A in the region and ongoing research to develop new treatment options for managing the condition. For example, in August 2018, the U.S. Food and Drug Administration (FDA) had approved Jivi (formerly BAY94-9027) used for the treatment and prophylaxis of bleeding in previously treated patients above the age of 12 years with hemophilia A. Jivi helps in replacing missing or reduced Factor VIII (FVIII), an important blood clotting protein in patients with the bleeding condition. North America was followed by Europe and Asia Pacific. In Asia Pacific, a considerable population of patients with hemophilia A and a rise in diagnosis rate are likely to fuel the hemophilia A treatment market during the forecast period.

Prominent players operating in the global hemophilia A treatment market include Pfizer, Inc., Kedrion, CSL Behring, Shire Plc., Bayer AG, Novo Nordisk A/S, Sanofi, and F. Hoffmann-La Roche Ltd..

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Hemophilia A Treatment Market

Pre Book